Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Antengene Announces Five Upcoming Presentations at the 2022 American Association for Cancer Research Annual Meeting 2022-03-09 20:00
Antengene Announces XPOVIO® Approved by the TGA in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Triple Class-Refractory Multiple Myeloma 2022-03-09 19:08
Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications 2022-03-02 08:47
Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037 2022-02-07 08:30
Antengene to Present at the 40th Annual J.P. Morgan Healthcare Conference 2022-01-05 12:50
Antengene Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors 2021-12-30 09:51
First Patient Dosed in Australia in ATG-101 First-in-Human Trial 2021-12-20 11:01
First Patient Dosed in Australia in ATG-101 First-in-Human Trial 2021-12-20 10:56
Antengene Announces NDA Approval by NMPA for XPOVIO®, China's First XPO1 inhibitor, for the Treatment of Adults with Relapsed or Refractory Multiple Myeloma 2021-12-17 22:27
Antengene and XtalPi Announce AI-Driven R&D Collaboration 2021-12-16 16:30
Antengene Presents Results of Phase 1b TOUCH Trial of Selinexor for the Treatment of T and NK-Cell Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting 2021-12-14 18:00
Antengene Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate ATG-017 in Combination with Opdivo® (nivolumab) in Advanced Solid Tumors 2021-12-13 08:30
Antengene Included in the MSCI Global Small Cap Indexes - MSCI China Index Constituent Stocks 2021-11-26 11:34
Treating Patients Beyond Borders - Antengene Successfully Hosted Its First R&D Day 2021-11-19 13:00
Antengene Announces IND Approval in China for a Phase I/II Study of Selinexor (ATG-010) in Patients with Non-Hodgkin Lymphoma 2021-11-19 08:30
Antengene Presents Compelling Preclinical Data on Two Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 12, 2021 2021-11-15 08:25
Antengene to Release Preliminary Results of Selinexor for the Treatment of Peripheral T-Cell Lymphoma and NK/T-Cell Lymphoma at the 2021 ASH Annual Meeting 2021-11-09 16:30
Antengene Granted IND Approval in China for the Phase Ib Study of ATG-008 (Onatasertib) in Combination with ATG-010 (Selinexor) in Patients with Diffuse Large B-Cell Lymphoma 2021-11-02 08:30
Antengene Receives FDA Approval of IND for Phase 1 Trial of ATG-101 (PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma 2021-11-01 08:40
Antengene to Host its First R&D Days on November 16 and November 18, 2021 2021-10-25 20:00
1 3 4 5 6 7 8